Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial

Michelino DeLaurentiis; Patrick Neven; Guy Heinrich Maria Jerusalem; Thomas Denis Bachelot; William Jacot; Susan Faye Dent; Marco Colleoni; Aleix Prat; Miguel Martin; Alistair E. Ring; Paul H. Cottu; Janice M. Lu; Hamdy A. Azim; Katie Zhou; Jiwen Wu; Juan Pablo Zarate; Claudio Zamagni

doi:10.1200/JCO.2018.36.15_suppl.1056

Retour

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial

Article de revue

Avec comité de lecture

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial

Michelino DeLaurentiis, Patrick Neven, Guy Heinrich Maria Jerusalem, Thomas Denis Bachelot, William Jacot, Susan Faye Dent, Marco Colleoni, Aleix Prat, Miguel Martin, Alistair E. Ring, …

Journal of clinical oncology, Vol.36(15_suppl), pp.1056-1056

20/05/2018

DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.1056

Résumé

Abstract only

Indicateurs

1 Consultations de la notice

Détails

Titre: Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial
Créateurs - sans rôle: Michelino DeLaurentiis - National Cancer Institute “Fondazione G. Pascale”, Napoli, Italy
Patrick Neven - University Hospitals Leuven, Leuven, Belgium
Guy Heinrich Maria Jerusalem - CHU Liege and University of Liege, Liège, Belgium
Thomas Denis Bachelot - Centre Léon Bérard
William Jacot - Institut du Cancer de Montpellier, Montpellier, France
Susan Faye Dent - The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
Marco Colleoni - European Institute of Oncology, Milan, Italy
Aleix Prat - Department of Medical Oncology, Hospital Clinic, Barcelona, Spain
Miguel Martin - Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain
Alistair E. Ring - The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Paul H. Cottu - Institut Curie
Janice M. Lu - Stony Brook Cancer Ctr, S Setauket, NY
Hamdy A. Azim - Cairo University, Cairo, Egypt
Katie Zhou - Novartis Pharmaceuticals Corporation, East Hanover, NJ
Jiwen Wu - Novartis Pharmaceuticals Corporation, East Hanover, NJ
Juan Pablo Zarate - Novartis Pharmaceuticals, East Hanover, NJ
Claudio Zamagni - Policlinico S. Orsola-Malpighi Hospital, Bologna, Italy
Détails de publication: Journal of clinical oncology, Vol.36(15_suppl), pp.1056-1056
Identifiants: 99140073509311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article